NEW YORK, March 9 (GenomeWeb News) - Astex Technology and Boehringer Ingelheim will collaborate to develop drugs for various indications, Astex said today.
Under the three-year agreement, Astex will use its X-ray crystallography-based technology to generate lead series against targets provided by Boehringer. Astex will receive an upfront payment, research funding, milestone payments and royalties on sales of products resulting from the collaboration. Boehringer, based in Ingelheim, Germany, will be responsible for all clinical development of compounds. Boehringer can also choose to obtain worldwide exclusive marketing rights to any compounds.
Astex, based in Cambridge, UK, determines how drug fragments bind to protein crystal structures and subsequently builds these fragments out into lead compounds. Astex also collaborates with Schering, AstraZeneca, Aventis Pharmaceuticals, Mitsubishi Pharma, Fujisawa Pharma, the Institute of Cancer Research UK, and Cancer Research Technology.